Alzamend Neuro (ALZN) Stock Price, News & Analysis

Company Overview

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease and other neurodegenerative or neuropsychiatric conditions. The company’s research is centered on therapies intended to address disease-related biological processes and improve the safety, tolerability, or delivery of existing treatment approaches.

Alzamend’s lead program, AL001, is an investigational lithium-based therapy designed as a proprietary ionic co-crystal of lithium salicylate and L-proline. The company is developing AL001 as a potential treatment for Alzheimer’s disease, with the goal of providing lithium’s potential neurological benefits while reducing some of the limitations associated with conventional lithium formulations.

The company has also developed AL002, an investigational immunotherapy candidate intended to stimulate an immune response against beta-amyloid, a protein associated with Alzheimer’s disease. Alzamend Neuro is headquartered in Atlanta, Georgia, and advances its programs through preclinical research and clinical development collaborations.

Key Stats

• Today's Range: $1.82 to $1.93
• 50-Day Range: $1.21 to $1.94
• 52-Week Range: $0.84 to $2.68
• Volume: 150,513 shs
• Average Volume: 113,953 shs
• Market Capitalization: $8.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.00
• Consensus Rating: Hold

Alzamend Neuro Stock Analysis - MarketRank™

Alzamend Neuro scored higher than 70% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Alzamend Neuro has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Alzamend Neuro has a consensus price target of $28.00, representing about 1,438.5% upside from its current price of $1.82.

Amount of Analyst Coverage

Alzamend Neuro has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alzamend Neuro are expected to grow in the coming year, from ($1.05) to ($0.87) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alzamend Neuro is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alzamend Neuro is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alzamend Neuro has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.58% of the float of Alzamend Neuro has been sold short.

Short Interest Ratio / Days to Cover

Alzamend Neuro has a short interest ratio ("days to cover") of 1.14, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alzamend Neuro has recently decreased by 22.16%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alzamend Neuro does not currently pay a dividend.

Dividend Growth

Alzamend Neuro does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Alzamend Neuro has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Alzamend Neuro this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for ALZN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Alzamend Neuro to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alzamend Neuro insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,120.00 in company stock.

Percentage Held by Insiders

1.39% of the stock of Alzamend Neuro is held by insiders.

Percentage Held by Institutions

49.61% of the stock of Alzamend Neuro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 9/10/2026
• Today: 9/25/2026
• Next Earnings (Estimated): 12/08/2026
• Fiscal Year End: 4/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALZN
• CIK: 1677077
• Web: www.alzamend.com
• Phone: (844) 722-6333
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Alzamend Neuro: $28.00
• High Price Target: $28.00
• Low Price Target: $28.00
• Potential Upside/Downside: +1,438.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -277.88%
• Return on Assets: -184.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.01
• Quick Ratio: 3.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.20 per share
• Price / Book: 1.52

Miscellaneous

• Outstanding Shares: 4,830,000
• Free Float: 4,759,000
• Market Cap: $8.79 million
• Optionable: No Data
• Beta: 0.23